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DOI: 10.1039/c0an00382dPrevious studies have indicated that volatile compounds specific to bladder cancer may exist in urine
headspace, raising the possibility that headspace analysis could be used for diagnosis of this particular
cancer. In this paper, we evaluate the use of a commercially available gas sensor array coupled with
a specifically designed pattern recognition algorithm for this purpose. The best diagnostic performance
that we were able to obtain with independent test data provided by healthy volunteers and bladder
cancer patients was 70% overall accuracy (70% sensitivity and 70% specificity). When the data of
patients suffering from other non-cancerous urological diseases were added to those of the healthy
controls, the classification accuracy fell to 65% with 60% sensitivity and 67% specificity. While this is
not sufficient for a diagnostic test, it is significantly better than random chance, leading us to conclude
that there is useful information in the urine headspace but that a more informative analytical technique,
such as mass spectrometry, is required if this is to be exploited fully.Introduction
Transitional cell carcinoma (TCC) of the bladder is the most
common form of bladder cancer and simultaneously the second
most common malignant tumour of the genito-urinary tract.1 As
with many cancers, untreated TCC can be fatal, so early detec-
tion is vitally important. Cystoscopy with biopsy is the ‘‘gold
standard’’ for bladder cancer detection, but it is expensive,
inconvenient and invasive. Urine cytology is a more acceptable
alternative, and the most widely applied of the non-invasive
procedures available. Although urine cytology has a high speci-
ficity for bladder cancer (90–98%), its sensitivity is low (20–50%),
especially for low-grade tumours, since those shed proportionally
few cells into the urine. Furthermore, the results take several
days, requiring an expert to interpret the test.1
Utilisation of molecular biomarkers for bladder cancer is
a tantalising prospect for making diagnosis more sensitive, rapid
and convenient, provided such biomarkers can be discovered in
urine and readily identified in a clinical setting. Two FDA
approved protein markers, nuclear matrix protein 22 (NMP22)
and bladder tumour antigen (BTAstat), have proven effective in
this context.2,3 They are more sensitive than urine cytology,
having achieved reported sensitivities of 50–85% and 50–70%,
respectively. However, their specificities, in the region of 60–70%,
are inferior to that of urine cytology.
Recently, it has been suggested that volatile organic
compounds (VOCs) present in the headspace of urine samples
may be used as cancer biomarkers.4,5 In particular, a previousaCranfield University, College Road, Cranfield, Bedfordshire, MK43 0AL,
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This journal is ª The Royal Society of Chemistry 2011study6 showed that dogs could be trained to identify bladder
cancer sufferers from the odour of their urine. The results of this
proof of principle study suggested that one or more VOCs
present within the urine headspace are indicative of bladder
cancer and have the potential to be used as diagnostic
biomarkers. As it is not realistic to use dogs in a clinical setting,
we substituted the dogs with a more practical and objective gas
sensor array, also called an electronic nose (eNose). Developed to
mimic olfaction, these instruments have shown promise in lung
cancer detection.7Methods
Participant selection
A total of 30 patients, aged 50–88, presenting at Buck-
inghamshire Hospitals NHS Trust with new or recurrent
transitional cell carcinoma (TCC) of the bladder supplied urine
prior to surgical intervention. Grade and stage of the tumour
were recorded. Fifty nine control subjects, categorised into one
of three groups (Controls 1, 2 and 3, depending upon age and
disease status), also provided urine samples. Twenty healthy
individuals aged 18–31, with no urine abnormality on dipstick
made up Control group 1 (C1). Control group 2 (C2) consisted
of 20 subjects between 18 and 32, with any non-cancerous
condition or disease, and/or one or more positive dipstick
finding. Menstruating women with blood in their urine were
included in this group, for example, as were individuals with
suspected urinary tract infection, positive for leucocytes, blood
and/or protein. Categorized into the Control 3 group (C3) were
19 patients, aged between 24 and 89, with confirmed non-
cancerous urological disease, with or without urine dipstick
abnormalities. Urological conditions included renal and
ureteric stones, renal cysts and polypoid cystitis. A summary of
the age and gender of the subjects in each cohort is included
as ESI†.Analyst, 2011, 136, 359–364 | 359
Fig. 1 Estimated sensor variables of an electronic nose. The analysis-
cycle of an electronic nose is composed of Baseline, Sample phase and
Recovery phase. During Sample phase and Recovery phase signal
parameters are calculated as baseline, response, absolute response, on
derivative, on integral, off derivative, off integral and difference. Those
parameters describe the reaction of a sensor to a certain compound.
Adapted from the manual of the eNose instrument.6
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View OnlineAs criteria for inclusion/exclusion, controls over 32 years of
age were required to have had recent cystoscopy to exclude
visible bladder malignancy. For both controls and the cancer
positive group (TCC), men over 50 years were only included if
recent cancer-negative prostate histology had been demon-
strated. Individuals with pre-malignant urological disease or
a history of urological carcinoma other than TCC were excluded.
A history of malignancy in other organ systems (>5 years
previously) was acceptable, providing the individual was now
considered disease-free. All other past and/or present medical
conditions were permissible. There were no exclusions on the
basis of medication, menstrual cycle, diet, alcohol consumption,
or chemical exposure. However, details of all of these factors
were recorded for each participant, should their influence on the
composition and odour of the urine need to be considered at any
stage. Special attention was paid to smoking habits, with one
third of those with bladder cancer being current cigarette
smokers, as compared to 17 out of 59 control subjects. A
spreadsheet containing all this information is provided as ESI†.
The study was approved by the Mid and South Buck-
inghamshire Local Research Ethics Committee, and all partici-
pants gave written informed consent.Analysis and processing of urine samples
Following urinalysis (Multistix 10 SG, Bayer Corporation, NY,
USA), fresh urine specimens were refrigerated immediately, and
frozen 1–24 h later as 0.5 ml aliquots in glass vials. They were
then stored at 80 C until required.Headspace analysis
An electronic nose was used to characterise the VOC (volatile
organic compound) content of urine. Measurements were per-
formed using an NST 3320 Lab Emission Analyser.8 The
instrument comprises 12 metal oxide semi-conductor (MOS)
sensors and an array of 10 individual metal oxide semi-conductor
field-effect transistor (MOSFET) sensors, together with
a capacitance-based humidity sensor and an infrared-based CO2
sensor.
The 89 urine samples were randomised, removed from storage
at 80 C and allowed to thaw at room temperature (approxi-
mately 21 C). The thawed samples were then aliquoted into two
headspace vials, each containing 2.5 ml of urine, providing
duplicate samples. The samples were then incubated for 1 hour at
38 C before they were analysed in batches of 12 samples using
the eNose. Signals from each of the 24 sensors are generated by
their response to the different chemical characteristics of the
urine headspace. The analysis was performed in cycles, exposing
the sensors to fresh reference air between the measurements. A
cycle was composed of Baseline, Sample and Recovery. During
runtime, all sensor signals were collected in periodic time inter-
vals of one second. From these resulting raw data, eight char-
acteristic signal parameters were estimated by the eNose software
as baseline, response, absolute response, on derivative, on integral,
off derivative, off integral and difference. This can be seen as data
reduction, very likely resulting in a speed up of subsequent
pattern recognition analysis. Fig. 1 shows the sensor parameters
graphically. All samples were measured twice (89 samples and360 | Analyst, 2011, 136, 359–36489 duplicates) and the resulting extracted signal parameters—
features—were finally exported in Microsoft Excel spreadsheet
format.Data analysis
The provided spreadsheet files were analysed using Matlab
R2009a (The Mathworks Inc.). Additionally the PLS Toolbox
3.5 (Eigenvector Research Inc.) was employed to classify the data
via partial least squares-discriminant analysis (PLS-DA). Before
the loaded data were analysed, the effect of data scaling was
investigated, with the methods considered being auto-scaling
(eqn (1)), mean-centring (eqn (2)), range-scaling between 0 and 1
(eqn (3)) and range-scaling between 1 and +1 (eqn (4)).9
yij ¼ xij  xj
sj
(1)
yij ¼ xij  xj (2)
yij ¼

xij min

xj


max

xj
minxj
 (3)
yij ¼
2 xij min

xj


max

xj
minxj
 1 (4)
Exploratory Data Analysis was accomplished via principal
component analysis (PCA), which is the most widely used
multivariate statistical technique.10–12 This part of the analysis
was performed to reveal the characteristics that cause the greatest
variance in the dataset.
Before the pre-processed data were sent to the classifier,
a crucial step—feature selection—was performed to provide the
classifier with the most significant variables, so as to achieveThis journal is ª The Royal Society of Chemistry 2011
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View Onlinehigher classification accuracy. This procedure resembles a filter
method that automatically picks out variables within the data
that are most distinctive of each class, or from another point of
view deselects those variables that are not significant at all. For
this purpose, univariate statistics—a t-test—was applied. The
t-test is more or less a decision rule to determine if two samples
belong to the same population, according to a specified signifi-
cance level a.13 Dependent on the significance level a, two vari-
ables, in this case, non-cancerous and cancerous samples, were
either considered as similar or different. For data analysis, the
significance level a was initially set to 0.05 and varied from 0.1 to
0.9 in steps of 0.1. Features whose probability value did not rise
above the threshold a were taken as being different and were
therefore regarded as relevant for disease-related discrimination.
From a statistical point of view high a-values are not suitable to
select significant features, but can be used to deselect insignificant
variables as noise for example.
Next, partial least squares discriminant analysis (PLS-DA)14
was used to build a classification model using the cancer status of
the samples. PLS-DA is a supervised method. This calls for
information about the parameter of interest (the cancer status) to
be known in order to train the algorithm to identify which
sensors capture the molecules that differentiate between the
classes. PLS-DA is considered to be a dimensionality reduction
method and can be seen as the regression extension of principal
component analysis.15 Unlike PCA, which attempts to describe
the maximum variation in the measured data, PLS-DA tends to
maximise the covariance between the input data and the output
class. The information returned by PCA is that which was caused
by the attribute with the biggest variance. In contrast, PLS-DA
returns only data that were caused by the property under
investigation.
It is known that PLS-DA is prone to overestimate the accuracy
of classification if it is not accurately validated.16 For this reason,
a very thorough evaluation process, leave-one-out cross-valida-
tion (LOOCV),17 was implemented to assess the performance of
the PLS-DA-classifier. This method is based on the concept of
classifying one sample against a model, built using the rest of the
samples. This procedure is repeated with each sample until all
samples have been classified. Information about the true positive
rate and the true negative rate was established.
As final validation of the results, and to attain an indication of
the significance of the results, a Monte Carlo Simulation was
used to evaluate the obtained results.18 This involves repeated
random sampling. In this context a null model is generated from
a set of data that is statistically similar to the data under study,
but for which we do not expect to be able to build a meaningful
classification model. A total of 250 datasets of this kind were
generated, by simply assigning a random class to each sample
(while maintaining the relative number of positive and negative
samples). For a disease discriminating model trained on the real
sample classes to be considered significant it needs to achieve
a classification accuracy towards the extremities of those
produced by the null models.Fig. 2 The PCA scores plot does not appear to show any discrimination
between cancerous ( ) and control samples of group C1 (B). The data
were pre-treated using range-scaling between 0 and 1.Results and discussion
The 24 sensors of the electronic nose instrument initially recor-
ded 192 sensor variables. However, during a later stage of theThis journal is ª The Royal Society of Chemistry 2011eNose analysis, significant random noise was identified in five of
the MOSFET sensors. As a consequence, the information
provided by these sensors was omitted from the data analysis.
Hence, 152 sensor variables (8 sensor variables  19 remaining
sensors) remained. To assess the role of the classification of each
sensor technology, we used the full array for classification as well
as only the MOS and only the MOSFET sensors to calculate
different classification models.
As already mentioned in the Methods section, the 59 speci-
mens belonging to the cancer-negative control group were sub-
divided into further subgroups (C1–C3). For this reason, we
sectioned our work into four main experiments. Firstly, each of
the three control subgroups was classified separately against the
cancer group and, finally, all control subgroups were combined
and classified together against the TCCs.
In each of the four experiments, we used the full sensor array
as well as the MOS sensors only and the MOSFET sensors only.
Furthermore we applied the same pre-processing methods to the
data, including scaling and feature selection. Four different
scaling methods and no scaling were evaluated, with range-
scaling between 0 and 1 being found to be the best; therefore,
only these results are shown in this paper. Given that we were
looking for a pattern within the data and were therefore inter-
ested in relative quantities, not absolute quantities, it is not
surprising that range-scaling was most appropriate.
Explorative data analysis, by way of PCA, was also applied in
each experiment to reveal natural groupings based on the sensor
responses of the electronic nose. The PCA scores plot derived
from the experimental data is shown in Fig. 2. However, the
visual output of this method did not disclose any relation to the
cancer status of the samples, even though the principal compo-
nents shown capture over 98% of the variance in the data. Other
influences such as age, diet or gender may be responsible for the
groupings obtained. However, this does not mean that the data
do not contain any information concerning bladder cancer. The
PCA only demonstrated that the cancer status is not responsible
for the bigger part of the variance, captured by the first two or
three principal components (PCs). Nevertheless, investigatingAnalyst, 2011, 136, 359–364 | 361
Table 1 Best results of leave-one-out cross-validation runs with PLS-
DA for each of the four experiments. The presented classification results
were obtained after scaling the data between zero and one and per-
forming feature selection
(a) C1 vs. TCC
Full sensor array
Significance level a 0.8
No. of features 140
Total accuracy 70.0%
Cancer group TCC accuracy (sensitivity) 70.0%
Control group C1 accuracy (specificity) 70.0%
MOSFET sensors
Significance level a 0.8
No. of features 35
Total accuracy 60.0%
Cancer group TCC accuracy (sensitivity) 61.7%
Control group C1 accuracy (specificity) 57.5%
MOS sensors
Significance level a 0.8
No. of features 91
Total accuracy 69.0%
Cancer group TCC accuracy (sensitivity) 68.3%
Control group C1 accuracy (specificity) 70.0%
(b) C2 vs. TCC
Full sensor array
Significance level a 0.1
No. of features 69
Total accuracy 67.0%
Cancer group TCC accuracy
(sensitivity)
71.7%
Control group C2 accuracy
(specificity)
60.0%
MOSFET sensors
Significance level a 0.1
No. of features 3
Total accuracy 65.0%
Cancer group TCC accuracy
(sensitivity)
65.0%
Control group C2 accuracy
(specificity)
65.0%
MOS sensors
Significance level a 0.1
No. of features 58
Total accuracy 59.0%
Cancer group TCC accuracy (sensitivity) 56.7%
Control group C2 accuracy (specificity) 62.5%
(c) C3 vs. TCC
Full sensor array
Significance level a 0.8
No. of features 132
Total accuracy 62.2%
Cancer group TCC accuracy (sensitivity) 68.3%
Control group
C3 accuracy (specificity)
52.6%
MOSFET sensors
Significance level a 0.8
No. of features 29
Total accuracy 57.1%
Cancer group TCC accuracy
(sensitivity)
61.7%
Control group C3 accuracy (specificity) 50.0%
MOS sensors
Significance level a 0.8
No. of features 87
Total accuracy 60.2%
Cancer group TCC accuracy
(sensitivity)
66.7%
Control group C3 accuracy (specificity) 50.0%
(d) C1, C2, C3 vs. TCC
Full sensor array
Significance level a 0.4
No. of features 110
Total accuracy 64.6%
Sensitivity 60.0%
Specificity 66.9%
Control group C1 accuracy 75.0%
Control group C2 accuracy 72.5%
Control group C3 accuracy 52.6%
Cancer group TCC accuracy 60.0%
MOSFET sensors
Significance level a 0.4
No. of features 13
Total accuracy 61.8%
Sensitivity 63.3%
Specificity 61.0%
Control group C1 accuracy 62.5%
Control group C2 accuracy 55.0%
Control group C3 accuracy 65.8%
Cancer group TCC accuracy 63.3%
MOS sensors
Significance level a 0.4
No. of features 83
Total accuracy 60.7%
Sensitivity 43.3%
Specificity 69.5%
Control group C1 accuracy 70.0%
Control group C2 accuracy 67.5%
Control group C3 accuracy 71.1%
Cancer group TCC accuracy 43.3%
362 | Analyst, 2011, 136, 359–364
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View Onlineprincipal components of lower variance did not lead to an
explicitly disease-related differentiation either. PLS-DA aims to
maximise the co-variation between the measured data and the
classification (non-cancerous vs. cancerous). This leads to the
capability to discriminate between samples that could not be
separated by PCA.
We started by training the PLS-DA-classifier with the two
most disparate groups: Control 1 (C1), representing healthy
males or females, and the TCC group incorporating people
suffering from bladder cancer. Since group C1 possesses the most
differences compared to the cancer group, we expected the
classification outcome of this sample set to be the best, which
proved to be correct. The best result obtained an overall total
accuracy of 70% by range-scaling the data and configuring the
significance level a ¼ 0.8 for feature selection. A summary of the
best classification results of C1 vs. TCC is given in Table 1a).
Next, we trained the classifier with Control 2 (C2) and the
cancer group (TCC) data. Urine samples within this control
subgroup showed similar abnormalities on dipstick analysis to
some cancer samples, such as blood, for example, and were
therefore more difficult to distinguish from cancerous samples
than Control 1 (C1) samples. Both specificity and the total
accuracy, achieved with the full sensor array, reflect this. Only
the sensitivity is marginally higher than that obtained for C1 vs.
TCC in full sensor array mode. An overview of the results
obtained is given in Table 1b).
In the third experiment, the classifier had to distinguish
between samples with confirmed non-cancerous urological
diseases (Control 3) and cancerous samples (TCC). This wasThis journal is ª The Royal Society of Chemistry 2011
Fig. 3 Distribution of the overall percentage classified after randomised assignation of classes to the samples corresponding to each of the four
experiments. Number of runs: 250. An achieved total accuracy that is beyond two standard deviations of the mean indicates that it is a significant result
at the 95% confidence level. (a) C1 vs. TCC: Control 1 (C1), representing healthy males or females, and the TCC group incorporating people suffering
from bladder cancer: total accuracy: 70%. (b) C2 vs. TCC: Control 2 (C2), representing urine samples showing similar abnormalities on dipstick analysis
to some cancer samples, and the TCC: total accuracy: 67%. (c) C3 vs. TCC: Control 3 (C3), representing samples with confirmed non-cancerous
urological diseases, and the TCC group: total accuracy: 67%. (d) C1, C2, C3 vs. TCC (using all available data): total accuracy: 64.61%.
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View Onlineexpected to be the most difficult combination, as disease markers
not specific to bladder cancer are likely to be present.
As far as the full sensor array is concerned sensitivity and
specificity as well as total accuracy did not reach the results
obtained in the two former experiments. A detailed overview of
these results is presented in Table 1c).
Finally, in the fourth experiment, all three control sub-
groups (C1, C2, and C3) were merged to form one control
group that was used as a counterpart to the TCC samples when
training the binary classifier. The results of this experiment can
be seen in Table 1d). As expected, the total accuracy, obtained
with the entire sensor array, was not as high as in experiments
1 and 2, where only samples from young people with no
urological disease (C1, C2) were included. The major contrib-
utor to this more moderate classification outcome was the
inclusion of the samples from Control group 3. All subjects
within this subgroup had confirmed non-cancerous urological
disease, the pathological effects of which are likely to be similar
to the secondary effects of bladder cancer. Within both these
groups, varying amounts of metabolic products associated with
inflammation, infection and/or necrosis will almost certainly be
present.This journal is ª The Royal Society of Chemistry 2011Because of this, Control 3 samples from the most important
control subset contain the most relevant information. Training
the classifier with this kind of data is therefore fundamental in
order to be able to subtract general disease compounds present in
the urine from those specific for bladder cancer. Accurate diag-
nosis of the control subjects is, of course, paramount to this
process, since the inclusion of false negative individuals would
lead to incorrect classification rules.
Interestingly, within the TCC sample group, the majority of
those incorrectly classified as negative were from patients with
more advanced tumours. In these cases, it is possible that
metabolic products generated secondarily to the tumour may
overwhelm or mask the volatile cancer biomarkers within the
urine, giving rise to a urine headspace more closely resembling
that of Control 3 samples. Canine olfactory studies support this
hypothesis; high grade TCCs with a significant level of invasion
are missed more frequently by trained dogs than low-grade
superficial tumours.19
To assess the significance of the presented results we carried
out Monte Carlo Simulations. Fig. 3 shows the results attained
for each of the four experiments each with 250 random runs. A
model with an overall accuracy beyond two standard deviationsAnalyst, 2011, 136, 359–364 | 363
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View Onlineof the mean indicates that it is a significant result at the 95%
confidence level. Thus, the first experiment that included totally
healthy volunteers and cancer patients and produced a total
accuracy of 70% is very significant (Fig. 3(a)). The result of the
second experiment, comprising samples showing abnormalities
at the dipstick analysis, can also be regarded as significant, with
an overall accuracy of 67% (Fig. 3(b)). The third experiment
included samples with confirmed non-cancerous urological
diseases and was therefore the most difficult to build classifiers
for. Not only did this experiment derive the lowest total
accuracy (62%), the accuracy was found to be just below 62.5%
that marks the 95% confidence limit in the null model results
(Fig. 3(c)). The fourth experiment made use of all available
data and attained a statistically significant classification result
of 65%, which comfortably exceeds the 95% confidence limit
(Fig. 3(d)).Conclusions
By combining a commercially available gas sensor array with
chemometrics techniques, we have made progress towards a new
instrumental method of bladder cancer detection based on
volatile biomarkers. As many as 70% of cancer patients and 70%
of non-cancerous subjects were correctly classified when the
classifier was trained with a combination of TCC positive urine
samples and samples from healthy participants with no urine
abnormality. PLS-DA-derived models gave an accuracy for
patients presenting with other non-cancerous urological disease
of 65%, with 60% sensitivity and 67% specificity. There is little
difference between the performance of the two sensor types used
in the array, but the results of the full array are consistently better
than the individual sets of sensors.
Although the specificity achieved using this method was less
than that of conventional urine cytology, sensitivity was
appreciably higher.1 This leads us to conclude that there is an
anomalous composition to the VOC content of urine of
patients suffering from bladder cancer, confirming previous
canine olfactory data.6 However, the gas sensor array may not
be the ideal analytical technique to detect this abnormal
composition of urine headspace. We therefore recommend
a more revealing analytical technique such as mass spec-
trometry. More sophisticated pattern recognition techniques as
support vector machines (SVMs)20 or artificial neural networks
(ANNs)21 may also further advance the results obtained so
far.364 | Analyst, 2011, 136, 359–364Acknowledgements
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